{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T13:36:29Z","timestamp":1777383389234,"version":"3.51.4"},"reference-count":82,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.phrs.2021.105456","type":"journal-article","created":{"date-parts":[[2021,1,27]],"date-time":"2021-01-27T11:47:23Z","timestamp":1611748043000},"page":"105456","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["A systematic review and dose-response meta-analysis on the efficacy of dapagliflozin in patients with type 1 diabetes mellitus"],"prefix":"10.1016","volume":"165","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2286-2181","authenticated-orcid":false,"given":"Ahmed","family":"Abu-Zaid","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdulaziz Khalaf","family":"Altowairqi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thusharika","family":"Dissanayaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Artem","family":"Oganesyan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akshaya Srikanth","family":"Bhagavathul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Habeeb","family":"Alhabeeb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amirah","family":"Baradhwan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Alomar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Tom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2021.105456_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2019.107843","article-title":"Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9(th) edition","volume":"157","author":"Saeedi","year":"2019","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.phrs.2021.105456_bib0010","series-title":"Type 1 Diabetes","author":"Federation","year":"2020"},{"issue":"Suppl 2","key":"10.1016\/j.phrs.2021.105456_bib0015","article-title":"Insulin: potential negative consequences of early routine use in patients with type 2 diabetes","volume":"34","author":"Lebovitz","year":"2011","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.phrs.2021.105456_bib0020","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.2337\/dc15-0090","article-title":"Evidence-informed clinical practice recommendations for treatment of type 1 diabetes complicated by problematic hypoglycemia","volume":"38","author":"Choudhary","year":"2015","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.phrs.2021.105456_bib0025","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1161\/CIRCULATIONAHA.111.077487","volume":"127","author":"Purnell","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2021.105456_bib0030","doi-asserted-by":"crossref","DOI":"10.1093\/bmb\/ldaa011","article-title":"Non-insulin therapies in addition to insulin in Type 1 DM treatment","author":"Llano","year":"2020","journal-title":"Br. Med. Bull."},{"key":"10.1016\/j.phrs.2021.105456_bib0035","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/dom.13749","article-title":"Sodium\u2010glucose co\u2010transporter inhibitors as adjunctive treatment to insulin in type 1 diabetes: a review of randomized controlled trials. Diabetes","volume":"21","author":"Boeder","year":"2019","journal-title":"Obe. Metab."},{"issue":"7","key":"10.1016\/j.phrs.2021.105456_bib0040","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nrd3180","article-title":"SGLT2 inhibition \u2014 a novel strategy for diabetes treatment","volume":"9","author":"Chao","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/j.phrs.2021.105456_bib0045","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/pdi.2222","article-title":"SGLT inhibitors for people with type 1 diabetes","volume":"36","author":"Llano","year":"2019","journal-title":"Pract. Diabetes"},{"issue":"9","key":"10.1016\/j.phrs.2021.105456_bib0050","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1210\/jc.2016-1451","article-title":"Dapagliflozin as additional treatment to liraglutide and insulin in patients with type 1 diabetes","volume":"101","author":"Kuhadiya","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.phrs.2021.105456_bib0055","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/dom.12882","article-title":"Dapagliflozin in patients with type 1 diabetes: a post hoc analysis of the effect of insulin dose adjustments on 24-hour continuously monitored mean glucose and fasting \u03b2-hydroxybutyrate levels in a phase IIa pilot study","volume":"19","author":"Henry","year":"2017","journal-title":"Diabetes Obes. Metab."},{"issue":"12","key":"10.1016\/j.phrs.2021.105456_bib0060","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.2337\/dc18-1087","article-title":"Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: the DEPICT-1 52-Week study","volume":"41","author":"Dandona","year":"2018","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.phrs.2021.105456_bib0065","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1111\/dom.13593","article-title":"Pharmacokinetics and pharmacodynamics of dapagliflozin in combination with insulin in Japanese patients with type 1 diabetes","volume":"21","author":"Watada","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.phrs.2021.105456_bib0070","doi-asserted-by":"crossref","DOI":"10.1111\/dom.14060","article-title":"Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 52-week results from a randomized controlled trial","author":"Mathieu","year":"2020","journal-title":"Diabetes Obes. Metab."},{"issue":"17","key":"10.1016\/j.phrs.2021.105456_bib0075","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1007\/s40265-019-01213-x","article-title":"Dapagliflozin: a review in type 1 diabetes","volume":"79","author":"Paik","year":"2019","journal-title":"Drugs"},{"issue":"15","key":"10.1016\/j.phrs.2021.105456_bib0080","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting","volume":"283","author":"Stroup","year":"2000","journal-title":"Jama"},{"key":"10.1016\/j.phrs.2021.105456_bib0085","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"Bmj"},{"issue":"12","key":"10.1016\/j.phrs.2021.105456_bib0090","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1002\/sim.3602","article-title":"Extending DerSimonian and Laird\u2019s methodology to perform multivariate random effects meta\u2010analyses","volume":"29","author":"Jackson","year":"2010","journal-title":"Stat. Med."},{"issue":"15","key":"10.1016\/j.phrs.2021.105456_bib0095","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1093\/jnci\/80.15.1198","article-title":"Regression models in clinical studies: determining relationships between predictors and response","volume":"80","author":"Harre Jr","year":"1988","journal-title":"JNCI: Journal of the National Cancer Institute."},{"key":"10.1016\/j.phrs.2021.105456_bib0100","series-title":"IDF Diabetes Atlas","author":"Federation","year":"2017"},{"issue":"2","key":"10.1016\/j.phrs.2021.105456_bib0105","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ijcard.2010.09.047","article-title":"Co-occurrence of metabolic factors and the risk of coronary heart disease: a prospective cohort study in the Netherlands","volume":"155","author":"Merry","year":"2012","journal-title":"Int. J. Cardiol."},{"issue":"1","key":"10.1016\/j.phrs.2021.105456_bib0110","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.endoen.2013.09.002","article-title":"Metabolic control and chronic complications during a 3-year follow-up period in a cohort of type 2 diabetic patients attended in primary care in the Community of Madrid (Spain)","volume":"61","author":"Arrieta","year":"2014","journal-title":"Endocrinolog\u00eda y Nutrici\u00f3n (English Edition)"},{"issue":"2","key":"10.1016\/j.phrs.2021.105456_bib0115","doi-asserted-by":"crossref","first-page":"320","DOI":"10.2337\/db12-0269","article-title":"Diabetes research: a perspective from the national institute of diabetes and digestive and kidney diseases","volume":"62","author":"Fradkin","year":"2013","journal-title":"Diabetes"},{"issue":"11","key":"10.1016\/j.phrs.2021.105456_bib0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0164977","article-title":"The humanistic burden of type 1 diabetes mellitus in Europe: examining health outcomes and the role of complications","volume":"11","author":"Ryd\u00e9n","year":"2016","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.phrs.2021.105456_bib0125","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1089\/dia.2019.0398","article-title":"Estimated lifetime economic burden of type 1 diabetes","volume":"22","author":"Sussman","year":"2020","journal-title":"Diabetes Technol. Ther."},{"issue":"7","key":"10.1016\/j.phrs.2021.105456_bib0130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0011501","article-title":"Estimating the cost of type 1 diabetes in the US: a propensity score matching method","volume":"5","author":"Tao","year":"2010","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.phrs.2021.105456_bib0135","doi-asserted-by":"crossref","first-page":"867","DOI":"10.2337\/dc19-2292","article-title":"Risk factors for first and subsequent CVD events in type 1 diabetes: the DCCT\/EDIC study","volume":"43","author":"Bebu","year":"2020","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.phrs.2021.105456_bib0140","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1210\/jc.2013-1589","article-title":"Severe hypoglycemia and diabetic ketoacidosis in adults with type 1 diabetes: results from the T1D Exchange clinic registry","volume":"98","author":"Weinstock","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"11","key":"10.1016\/j.phrs.2021.105456_bib0145","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/(SICI)1096-9136(199711)14:11<919::AID-DIA456>3.0.CO;2-A","article-title":"Risk of adverse effects of intensified treatment in insulin\u2010dependent diabetes mellitus: a meta\u2010analysis","volume":"14","author":"Egger","year":"1997","journal-title":"Diabet. Med."},{"key":"10.1016\/j.phrs.2021.105456_bib0150","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1001\/jama.1996.03540170053032","article-title":"Lifetime benefits and costs of intensive therapy as practiced in the Diabetes Control and Complications Trial","volume":"276","author":"DCCT","year":"1996","journal-title":"Jama"},{"issue":"9","key":"10.1016\/j.phrs.2021.105456_bib0155","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/S2213-8587(16)00039-5","article-title":"Non-insulin drugs to treat hyperglycaemia in type 1 diabetes mellitus","volume":"4","author":"Frandsen","year":"2016","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"11","key":"10.1016\/j.phrs.2021.105456_bib0160","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1111\/dme.13455","article-title":"HbA1c variability is associated with increased mortality and earlier hospital admission in people with Type 1 diabetes","volume":"34","author":"Walker","year":"2017","journal-title":"Diabet. Med."},{"key":"10.1016\/j.phrs.2021.105456_bib0165","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/S0002-9149(99)80683-3","article-title":"Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial","volume":"75","author":"Control","year":"1995","journal-title":"Am. J. Cardiol."},{"issue":"2","key":"10.1016\/j.phrs.2021.105456_bib0170","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1001\/jama.280.2.140","article-title":"Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT","volume":"280","author":"Purnell","year":"1998","journal-title":"Jama"},{"key":"10.1016\/j.phrs.2021.105456_bib0175","first-page":"349","article-title":"Safety, effectiveness, and cost effectiveness of long acting versus intermediate acting insulin for patients with type 1 diabetes: systematic review and network meta-analysis","author":"Tricco","year":"2014","journal-title":"bmj."},{"issue":"6","key":"10.1016\/j.phrs.2021.105456_bib0180","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/j.1463-1326.2006.00686.x","article-title":"Insulin\u2010associated weight gain in diabetes\u2013causes, effects and coping strategies","volume":"9","author":"Russell\u2010Jones","year":"2007","journal-title":"Diabetes Obes. Metab."},{"issue":"2","key":"10.1016\/j.phrs.2021.105456_bib0185","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1089\/dia.2018.0384","article-title":"State of type 1 diabetes management and outcomes from the T1D Exchange in 2016\u20132018","volume":"21","author":"Foster","year":"2019","journal-title":"Diabetes Technol. Ther."},{"key":"10.1016\/j.phrs.2021.105456_bib0190","doi-asserted-by":"crossref","DOI":"10.1111\/dom.14069","article-title":"Undertreatment of cardiovascular risk factors in the type 1 diabetes exchange clinic network (United States) and the prospective diabetes follow\u2010up (Germany\/Austria) registries","author":"Shah","year":"2020","journal-title":"Diabetes Obes. Metab."},{"issue":"10","key":"10.1016\/j.phrs.2021.105456_bib0195","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.2337\/dc15-0780","article-title":"Rates of diabetic ketoacidosis: international comparison with 49,859 pediatric patients with type 1 diabetes from England, Wales, the US, Austria, and Germany","volume":"38","author":"Maahs","year":"2015","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.phrs.2021.105456_bib0200","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1111\/dme.12676","article-title":"Glycaemic control of Type 1 diabetes in clinical practice early in the 21st century: an international comparison","volume":"32","author":"McKnight","year":"2015","journal-title":"Diabet. Med."},{"issue":"11","key":"10.1016\/j.phrs.2021.105456_bib0205","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1111\/j.1464-5491.2004.01319.x","article-title":"Amylin replacement with pramlintide as an adjunct to insulin therapy improves long\u2010term glycaemic and weight control in Type 1 diabetes mellitus: a 1\u2010year, randomized controlled trial","volume":"21","author":"Ratner","year":"2004","journal-title":"Diabet. Med."},{"issue":"3","key":"10.1016\/j.phrs.2021.105456_bib0210","doi-asserted-by":"crossref","first-page":"136","DOI":"10.3810\/pgm.2013.05.2635","article-title":"Pramlintide improved measures of glycemic control and body weight in patients with type I diabetes mellitus undergoing continuous subcutaneous insulin infusion therapy","volume":"125","author":"Herrmann","year":"2013","journal-title":"Postgrad. Med."},{"issue":"10","key":"10.1016\/j.phrs.2021.105456_bib0215","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.2337\/dc06-0042","article-title":"A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes","volume":"29","author":"Edelman","year":"2006","journal-title":"Diabetes Care"},{"issue":"04","key":"10.1016\/j.phrs.2021.105456_bib0220","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1055\/s-2005-837662","article-title":"Adjunctive therapy with pramlintide lowers HbA1c without concomitant weight gain and increased risk of severe hypoglycemia in patients with type 1 diabetes approaching glycemic targets","volume":"113","author":"Ratner","year":"2005","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"issue":"4","key":"10.1016\/j.phrs.2021.105456_bib0225","doi-asserted-by":"crossref","first-page":"724","DOI":"10.2337\/diacare.25.4.724","article-title":"A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes","volume":"25","author":"Whitehouse","year":"2002","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.phrs.2021.105456_bib0230","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.2337\/dc16-0691","article-title":"Efficacy and safety of liraglutide added to insulin treatment in type 1 diabetes: the ADJUNCT ONE treat-to-target randomized trial","volume":"39","author":"Mathieu","year":"2016","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.phrs.2021.105456_bib0235","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.2337\/dc16-0690","article-title":"Efficacy and safety of liraglutide added to capped insulin treatment in subjects with type 1 diabetes: the ADJUNCT TWO randomized trial","volume":"39","author":"Ahr\u00e9n","year":"2016","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.phrs.2021.105456_bib0240","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.2337\/dc15-1136","article-title":"Addition of liraglutide to insulin in patients with type 1 diabetes: a randomized placebo-controlled clinical trial of 12 weeks","volume":"39","author":"Kuhadiya","year":"2016","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.phrs.2021.105456_bib0245","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1530\/EJE-11-0330","article-title":"Liraglutide as additional treatment for type 1 diabetes","volume":"165","author":"Varanasi","year":"2011","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.phrs.2021.105456_bib0250","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2018.04.018","article-title":"Sodium glucose cotransporters inhibitors in type 1 diabetes","volume":"133","author":"Dellepiane","year":"2018","journal-title":"Pharmacol. Res."},{"issue":"3","key":"10.1016\/j.phrs.2021.105456_bib0255","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S2213-8587(15)00436-2","article-title":"Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial","volume":"4","author":"Dejgaard","year":"2016","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"6","key":"10.1016\/j.phrs.2021.105456_bib0260","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1111\/dom.12830","article-title":"Liraglutide as adjunct to insulin treatment in type 1 diabetes does not interfere with glycaemic recovery or gastric emptying rate during hypoglycaemia: a randomized, placebo\u2010controlled, double\u2010blind, parallel\u2010group study","volume":"19","author":"Frandsen","year":"2017","journal-title":"Diabetes Obes. Metab."},{"issue":"8","key":"10.1016\/j.phrs.2021.105456_bib0265","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/dom.12473","article-title":"Counter\u2010regulatory hormone responses to hypoglycaemia in people with type 1 diabetes after 4 weeks of treatment with liraglutide adjunct to insulin: a randomized, placebo\u2010controlled, double\u2010blind, crossover trial","volume":"17","author":"Pieber","year":"2015","journal-title":"Diabetes Obes. Metab."},{"issue":"2","key":"10.1016\/j.phrs.2021.105456_bib0270","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/dmrr.2486","article-title":"Steroid\u2010induced diabetes: a clinical and molecular approach to understanding and treatment","volume":"30","author":"Hwang","year":"2014","journal-title":"Diabetes Metab. Res. Rev."},{"issue":"2","key":"10.1016\/j.phrs.2021.105456_bib0275","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1152\/physrev.00055.2009","article-title":"Biology of human sodium glucose transporters","volume":"91","author":"Wright","year":"2011","journal-title":"Physiol. Rev."},{"issue":"12","key":"10.1016\/j.phrs.2021.105456_bib0280","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.2337\/dc15-1730","article-title":"Efficacy and safety of canagliflozin, a sodium\u2013glucose cotransporter 2 inhibitor, as add-on to insulin in patients with type 1 diabetes","volume":"38","author":"Henry","year":"2015","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.phrs.2021.105456_bib0285","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2337\/dc16-1353","article-title":"The effect of canagliflozin, a sodium glucose cotransporter 2 inhibitor, on glycemic end points assessed by continuous glucose monitoring and patient-reported outcomes among people with type 1 diabetes","volume":"40","author":"Rodbard","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.phrs.2021.105456_bib0290","article-title":"Diabetic ketoacidosis with canagliflozin, a sodium\u2013Glucose cotransporter 2 inhibitor","author":"Thakkar","year":"2016","journal-title":"Patients With Type 1 Diabetes"},{"issue":"5","key":"10.1016\/j.phrs.2021.105456_bib0295","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.2337\/dc13-2338","article-title":"Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial","volume":"37","author":"Perkins","year":"2014","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.phrs.2021.105456_bib0300","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1111\/dom.12494","article-title":"Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4\u2010week, randomized, placebo\u2010controlled trial (EASE\u20101)","volume":"17","author":"Pieber","year":"2015","journal-title":"Diabetes Obes. Metab."},{"issue":"12","key":"10.1016\/j.phrs.2021.105456_bib0305","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.2337\/dc18-1749","article-title":"Empagliflozin as adjunctive to insulin therapy in type 1 diabetes: the EASE trials","volume":"41","author":"Rosenstock","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.phrs.2021.105456_bib0310","first-page":"365","article-title":"Efficacy and safety of dual SGLT 1\/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials","author":"Musso","year":"2019","journal-title":"bmj"},{"key":"10.1016\/j.phrs.2021.105456_bib0315","series-title":"European Medicines Agency","year":"2020"},{"issue":"8","key":"10.1016\/j.phrs.2021.105456_bib0320","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/1753-0407.12890","article-title":"Safety and efficacy of sodium glucose co\u2010transporter 2 inhibitors combined with insulin in adults with type 1 diabetes: a meta\u2010analysis of randomized controlled trials","volume":"11","author":"Li","year":"2019","journal-title":"J. Diabetes"},{"issue":"7","key":"10.1016\/j.phrs.2021.105456_bib0325","doi-asserted-by":"crossref","first-page":"e3169","DOI":"10.1002\/dmrr.3169","article-title":"Effects of sodium\u2010glucose cotransporter (SGLT) inhibitors in addition to insulin therapy on glucose control and safety outcomes in adults with type 1 diabetes: a meta\u2010analysis of randomized controlled trials","volume":"35","author":"Lu","year":"2019","journal-title":"Diabetes Metab. Res. Rev."},{"issue":"1","key":"10.1016\/j.phrs.2021.105456_bib0330","doi-asserted-by":"crossref","first-page":"22","DOI":"10.24920\/J1001-9242.2007.003","article-title":"Efficacy and safety of SGLT2 inhibitors in patients with type 1 diabetes: a meta-analysis of randomized controlled trials","volume":"32","author":"Yang","year":"2017","journal-title":"Chinese Med. Sci. J."},{"key":"10.1016\/j.phrs.2021.105456_bib0335","doi-asserted-by":"crossref","first-page":"44128","DOI":"10.1038\/srep44128","article-title":"The efficacy and safety of SGLT2 inhibitors for adjunctive treatment of type 1 diabetes: a systematic review and meta-analysis","volume":"7","author":"Chen","year":"2017","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.phrs.2021.105456_bib0340","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/dom.12594","article-title":"Comparison of the pharmacokinetics and pharmacodynamics of dapagliflozin in patients with type 1 versus type 2 diabetes mellitus","volume":"18","author":"Tang","year":"2016","journal-title":"Diabetes Obes. Metab."},{"issue":"2","key":"10.1016\/j.phrs.2021.105456_bib0345","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00125-016-4157-3","article-title":"Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition","volume":"60","author":"Vallon","year":"2017","journal-title":"Diabetologia"},{"issue":"10","key":"10.1016\/j.phrs.2021.105456_bib0350","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.phrs.2021.105456_bib0355","doi-asserted-by":"crossref","first-page":"45","DOI":"10.15277\/bjdvd.2014.014","article-title":"Alpha cell function in type 1 diabetes","volume":"14","author":"Hughes","year":"2014","journal-title":"Br. J. Diabetes"},{"issue":"1","key":"10.1016\/j.phrs.2021.105456_bib0360","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s40200-015-0210-x","article-title":"Dapagliflozin as an adjunct therapy to insulin in the treatment of patients with type 1 diabetes mellitus","volume":"14","author":"Tamez","year":"2015","journal-title":"J. Diabetes Metab. Disord."},{"issue":"11","key":"10.1016\/j.phrs.2021.105456_bib0365","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1111\/dme.12840","article-title":"Response to Rosival: pathophysiology of diabetic ketoacidosis","volume":"32","author":"Misra","year":"2015","journal-title":"Diabet. Med."},{"issue":"5","key":"10.1016\/j.phrs.2021.105456_bib0370","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/nm.3828","article-title":"Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion","volume":"21","author":"Bonner","year":"2015","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.phrs.2021.105456_bib0375","doi-asserted-by":"crossref","first-page":"e2886","DOI":"10.1002\/dmrr.2886","article-title":"Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: basic mechanisms and therapeutic perspectives","volume":"33","author":"Qiu","year":"2017","journal-title":"Diabetes Metab. Res. Rev."},{"issue":"9","key":"10.1016\/j.phrs.2021.105456_bib0380","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.2337\/dc15-0843","article-title":"Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium\u2013glucose cotransporter 2 inhibition","volume":"38","author":"Peters","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.phrs.2021.105456_bib0385","series-title":"Overview | Dapagliflozin with insulin for treating type 1 diabetes | Guidance | NICE","year":"2020"},{"key":"10.1016\/j.phrs.2021.105456_bib0390","series-title":"Forxiga - European Medicines Agency","year":"2018"},{"key":"10.1016\/j.phrs.2021.105456_bib0395","series-title":"A Selective Sodium-glucose Transporter (SGLT2) Inhibitor Forxiga Receives Additional Regulatory Approval on Indication and Dosage and Administration in type-1 Diabetes in Japan","first-page":"2019","author":"AstraZeneca","year":"2019"},{"key":"10.1016\/j.phrs.2021.105456_bib0400","series-title":"Dapagliflozin for Type 1 Diabetes: Ensuring Benefits Outweigh The Risks","author":"Erskine","year":"2020"},{"issue":"6","key":"10.1016\/j.phrs.2021.105456_bib0405","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.2337\/dc18-2316","article-title":"International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with sodium\u2013glucose cotransporter (SGLT) inhibitors","volume":"42","author":"Danne","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.phrs.2021.105456_bib0410","first-page":"1","article-title":"Optimising the benefits of SGLT2 inhibitors for type 1 diabetes","author":"Evans","year":"2020","journal-title":"Diabetes Ther."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661821000396?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661821000396?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:18:19Z","timestamp":1760912299000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661821000396"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":82,"alternative-id":["S1043661821000396"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2021.105456","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A systematic review and dose-response meta-analysis on the efficacy of dapagliflozin in patients with type 1 diabetes mellitus","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2021.105456","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105456"}}